Type 2 Diabetes Therapy

Good safety results found in phase 1 trial of GLP-1 therapy for type 2 diabetes

Published in Obesity and Diabetes Week, April 25th, 2005

Theratechnologies (TH) announced good safety results testing TH0318, a glucagon-like peptide-1 (GLP-1) analogue in healthy volunteers.

The company is currently assessing recent clinical developments involving other GLP-1 analogues to determine the best way to position itself competitively in the market for this new class of drugs.

The primary objective of the phase 1 study was to demonstrate the safety of TH0318 through a randomized, single-center, dose-escalation, parallel, placebo-controlled trial. The study population consisted of 36 healthy male volunteers, aged 18 to 45, divided into 6 cohorts. TH0318 was administered by subcutaneous injection...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-04-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry